Krsnaa Diagnost.

Q1 FY26

Krsnaa Diagnost. Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹562

Market cap₹1.9K Cr

P/E19.2

Updated23 Aug 2026

Read4 min read

The short version

Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns. EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.

From Krsnaa Diagnost.'s Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns.
Management expects volume and revenue growth to be higher than industry averages going forward.
Rajasthan PPP contract rollout underway; full implementation of labs and collection centers expected over 6-9 months, with meaningful revenue from next financial year.
Retail diagnostics (RPL) rapidly scaling, contributing ~6% of revenues; expected to grow to 5%-8% by FY '26.
Retail business targeted to breakeven by FY '26 with 18%-20% revenue contribution anticipated within 1-1.5 years.
Expansion in Maharashtra, Punjab, Assam, and Odisha, leveraging PPP backbone to accelerate retail growth.

2 more points management made on revenue & sales performance

Profitability & Margins

EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.
Profit after tax increased 15% YoY to INR 205 million with an 11% margin.
Earnings per share rose 14% YoY to INR 6.25 in Q1 FY '26.
Retail revenue expected to contribute 5% to 8% of total revenue by FY '26, driving growth.
The Rajasthan PPP contract will add INR 300-350 crores revenue starting FY '27, supporting top-line growth.
EBITDA breakeven for retail venture expected by end of FY '26.
The company targets revenue growth better than industry average (~15-16%) going forward.

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Rajasthan PPP project: CAPEX increased to around INR 200-250 crores, involving 42 mother labs, 135 satellite labs, and 1,335 collection centers; rollout phased over next 6-9 months, with revenues starting FY '27.
Apulki partnership: Investments in MRI, CT, and pathology equipment (likely INR 10 crores+), with strategic intent for long-term (30 years) revenue visibility; no change in stake currently discussed.
Maharashtra radiology expansion: Completion of major portion (75%) of 73 centers including CT and MRI by end of Q3.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

For the Rajasthan project CAPEX of INR 200-250 crores, Krsnaa Diagnostics is evaluating multiple funding options.
Funding sources being considered include a combination of internal accruals, debt at efficient cost of capital, and leasing or reagent rental models.
There is no explicit mention of a new equity fundraising currently.

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company is actively pursuing tenders but it is too early to provide specific details about the current tender pipeline.
As tenders come up, the company will share details accordingly.
The Rajasthan PPP contract is a major new order with CAPEX estimated around INR 200-250 crores, expected to start generating revenues from FY 2027.
The Rajasthan project includes 42 mother labs, 135 satellite labs, and over 1,300 collection centers targeted for full operations by FY 2026.
There is ongoing implementation and expansion of radiology and pathology centers in Maharashtra, Madhya Pradesh, and Uttar Pradesh within the current order book.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q1 FY26 results?

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

Rajasthan PPP project: CAPEX increased to around INR 200-250 crores, involving 42 mother labs, 135 satellite labs, and 1,335 collection centers; rollout phased over next 6-9 months, with revenues starting FY '27.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.